English
Bactiguard is a global MedTech company dedicated to advancing patient safety by developing safe, biocompatible solutions that prevent medical device-related infections. Our unique technology is based on an ultra-thin noble metal coating that reduces bacterial adhesion and biofilm formation key contributors to healthcare-associated infections. Bactiguard undertook a strategic review in 2023 and sharpened their strategy and business model to focus on proprietary platform technologies commercialized through license partnerships within medical devices.
Bactiguard had a proprietary product portfolio of coated products sold under its brand and that are still displayed on the homepage. In connection with the strategic review, sales of these products are being discontinued, in favor of focusing resources on partnerships with other medical device companies with the core technology platform, including potentially these previously sold products.
Bactiguard is a global MedTech company developing safe and biocompatible technology to prevent medical device related infections. The company’s unique technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard’s infection prevention technology and solutions decrease patient suffering, save lives, and unburden healthcare resources while also fighting against antimicrobial resistance, one of the most serious threats to global health and modern medicine.
Bactiguard operates through license partnerships with leading global MedTech companies that apply the technology to their medical devices and sell them under their own brand or co-branded with Bactiguard. The company also has a portfolio of wound management products. Bactiguard is headquartered in Stockholm and listed on Nasdaq Stockholm.
Our story began in 2005, building on a rich legacy that dates back to 1912 with Nobel Laureate Gustav Dahlén. The infection prevention technology at the heart of Bactiguard was pioneered by Billy Södervall in the 1970s and achieved FDA approval in 1994. Since then, we’ve continued to grow through strategic partnerships — including collaborations with BD (Becton, Dickinson & Company) in 1990 and Zimmer Biomet in 2019.
Following our public listing on Nasdaq Stockholm in 2014, we’ve expanded our product portfolio and global presence. Key milestones include the acquisition of Vigilenz Medical Devices and the addition of innovative wound care solutions.
Today, Bactiguard focuses on licensing its proprietary technology to leading global MedTech companies, while also offering a range of in-house wound management products. Our mission is to reduce patient suffering, save lives, and ease the burden on healthcare systems, while contributing to the global fight against antimicrobial resistance one of the greatest health challenges of our time.
Headquartered in Stockholm, Sweden, Bactiguard is listed on Nasdaq Stockholm. We employ around 50 people in Sweden and 150 across Asia, working together to drive safer healthcare forward.
Our Mission
At Bactiguard, our mission is to save lives and protect people by preventing healthcare-associated infections. Through our innovative and biocompatible coating technology, we reduce the risk of infection and the need for antibiotics supporting global efforts to combat antimicrobial resistance and improve patient safety worldwide.
For more information, visit the company´s web sites at https://www.bactiguard.com
Bactiguard had a proprietary product portfolio of coated products sold under its brand and that are still displayed on the homepage. In connection with the strategic review, sales of these products are being discontinued, in favor of focusing resources on partnerships with other medical device companies with the core technology platform, including potentially these previously sold products.
Bactiguard is a global MedTech company developing safe and biocompatible technology to prevent medical device related infections. The company’s unique technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard’s infection prevention technology and solutions decrease patient suffering, save lives, and unburden healthcare resources while also fighting against antimicrobial resistance, one of the most serious threats to global health and modern medicine.
Bactiguard operates through license partnerships with leading global MedTech companies that apply the technology to their medical devices and sell them under their own brand or co-branded with Bactiguard. The company also has a portfolio of wound management products. Bactiguard is headquartered in Stockholm and listed on Nasdaq Stockholm.
Our story began in 2005, building on a rich legacy that dates back to 1912 with Nobel Laureate Gustav Dahlén. The infection prevention technology at the heart of Bactiguard was pioneered by Billy Södervall in the 1970s and achieved FDA approval in 1994. Since then, we’ve continued to grow through strategic partnerships — including collaborations with BD (Becton, Dickinson & Company) in 1990 and Zimmer Biomet in 2019.
Following our public listing on Nasdaq Stockholm in 2014, we’ve expanded our product portfolio and global presence. Key milestones include the acquisition of Vigilenz Medical Devices and the addition of innovative wound care solutions.
Today, Bactiguard focuses on licensing its proprietary technology to leading global MedTech companies, while also offering a range of in-house wound management products. Our mission is to reduce patient suffering, save lives, and ease the burden on healthcare systems, while contributing to the global fight against antimicrobial resistance one of the greatest health challenges of our time.
Headquartered in Stockholm, Sweden, Bactiguard is listed on Nasdaq Stockholm. We employ around 50 people in Sweden and 150 across Asia, working together to drive safer healthcare forward.
Our Mission
At Bactiguard, our mission is to save lives and protect people by preventing healthcare-associated infections. Through our innovative and biocompatible coating technology, we reduce the risk of infection and the need for antibiotics supporting global efforts to combat antimicrobial resistance and improve patient safety worldwide.
For more information, visit the company´s web sites at https://www.bactiguard.com
Vice President QARA
Bactiguard is seeking an experienced and strategic Vice President Quality Assurance and Regulatory Affairs to lead and develop their global QA/RA function. VP QARA will ensure that the Quality Management System (QMS) remains robust, compliant, and aligned with their growth ambitions, product development efforts, and global market access requirements.
Bactiguard is on a mission to reduce the risk of healthcare-associated infections and save lives through infection prevention. As Vice President QARA, you will play a key strategic role in transforming Bactiguard’s QMS in line with the new licensing strategy, thereby ensuring our innovative technology and required deliverables to our partners meet global quality and regulatory standards.
In this senior leadership role, you will oversee QA/RA activities globally, with a primary focus on maintaining and enhancing compliance with MDR, FDA, and other international regulatory frameworks. You will also lead a dedicated and skilled team, working cross-functionally with R&D, Manufacturing, Business Development, Clinical Affairs and Chief Scientific Officer to embed a quality-first mindset throughout the organisation.
You will have the opportunity to contribute to the development of Bactiguard’s future licensing business, bringing your expertise to guide strategic decisions. This is a high-impact role for a quality and regulatory compliance expert who is passionate about patient safety, innovation, and continuous improvement.
We are seeking an experienced leader with a strong background in medical devices. You bring a robust understanding of ISO 13485, along with a collaborative approach and solution-oriented mindset. You know how to translate complex regulatory requirements into efficient processes that support the business.
This is a full-time, permanent position based at our headquarters in Stockholm, Sweden.
Qualification
• University degree in Life Sciences (e.g. Chemistry, Biology, Pharmacy, Medicine, Engineering)
• Long and robust experience of QA within Medical Device industry, and ISO 13485
• Proven experience of product development and manufacturing, according to ISO 13485 and QSR
• Strong background in quality control, quality assurance, supplier audits, risk management, and compliance leadership
Competencies
• Structured and agile working style – comfortable in fast-moving environments
• Strong communication and stakeholder management skills – from team to executive level
• Team-oriented leader who thrives under pressure and takes initiative
• Strategic thinker with a hands-on, pragmatic approach to implementation
• Fluent in English and Swedish (written and spoken)
• Willingness to travel to Markaryd occasionally as and when needed
Opportunities with the role
• Be part of a product journey that contributes to the global fight against antimicrobial resistance
• Lead the transformation of our QMS and support new product development in an innovative company
• Opportunity to grow and shape a future-proof QA/RA function
• Hybrid work and flexibility
• Work in a high-impact, visible role with international reach
Contact
For more information and questions about the position, please contact Marta Frick Senior Recruitment Consultant or Lucy Robertshaw, Recruitment Consultant at PeakSearch.
Contact details:
Marta Frick marta.frick@peaksearch.se Tel: 070-386 89 69
Lucy Robertshaw lucy.robertshaw@peaksearch.se, 070-628 02 30